Avantor 과거 수익 실적
과거 기준 확인 2/6
Avantor은 연평균 37.4%의 비율로 수입이 증가해 온 반면, Life Sciences 산업은 수입이 증가했으며, 연간 11.7%였습니다. 매출은 연평균 3.2%의 비율로 증가했습니다. Avantor의 자기자본이익률은 5.6%이고 순이익률은 4.5%입니다.
주요 정보
37.4%
수익 성장률
42.1%
EPS 성장률
| Life Sciences 산업 성장 | 21.5% |
| 매출 성장률 | 3.2% |
| 자기자본 수익률 | 5.6% |
| 순이익 | 4.5% |
| 최근 수익 업데이트 | 30 Sep 2024 |
최근 과거 실적 업데이트
Recent updates
Are Investors Undervaluing Avantor, Inc. (NYSE:AVTR) By 28%?
Nov 16
Avantor (NYSE:AVTR) Takes On Some Risk With Its Use Of Debt
Oct 26Avantor: Uninspiring, Even Amidst Some Green Shoots
Oct 24Why We're Not Concerned About Avantor, Inc.'s (NYSE:AVTR) Share Price
Sep 02Avantor, Inc. (NYSE:AVTR) Shares Could Be 35% Below Their Intrinsic Value Estimate
Aug 15Avantor: Yet To Evidence Economic Value For Valuation Repricing, Reiterate Hold
Aug 13At US$20.82, Is Avantor, Inc. (NYSE:AVTR) Worth Looking At Closely?
Jul 16We Think Avantor (NYSE:AVTR) Is Taking Some Risk With Its Debt
May 22Are Investors Undervaluing Avantor, Inc. (NYSE:AVTR) By 32%?
Apr 26Avantor, Inc.'s (NYSE:AVTR) Popularity With Investors Is Clear
Apr 04We Think You Can Look Beyond Avantor's (NYSE:AVTR) Lackluster Earnings
Feb 21Is Avantor (NYSE:AVTR) A Risky Investment?
Feb 11Should You Think About Buying Avantor, Inc. (NYSE:AVTR) Now?
Jan 21Getting In Cheap On Avantor, Inc. (NYSE:AVTR) Might Be Difficult
Dec 31Are Investors Undervaluing Avantor, Inc. (NYSE:AVTR) By 23%?
Dec 09Avantor: Contracting Growth And Returns On Equity At 37x Earnings - Enemies To The Value Investor
Dec 01These 4 Measures Indicate That Avantor (NYSE:AVTR) Is Using Debt Extensively
Oct 24Is Now An Opportune Moment To Examine Avantor, Inc. (NYSE:AVTR)?
Oct 03Is There An Opportunity With Avantor, Inc.'s (NYSE:AVTR) 32% Undervaluation?
Sep 10Avantor: Customers Destocking, Order Volumes Down, Challenges To Rating (Rating Downgrade)
Sep 08Avantor (NYSE:AVTR) Has A Pretty Healthy Balance Sheet
Jul 10Avantor: Promising Long-Term Buy With Potential For Opportunistic Entry
Jun 28At US$19.71, Is Avantor, Inc. (NYSE:AVTR) Worth Looking At Closely?
Jun 22A Look At The Fair Value Of Avantor, Inc. (NYSE:AVTR)
Jun 04Do Avantor's (NYSE:AVTR) Earnings Warrant Your Attention?
Apr 17Is Avantor (NYSE:AVTR) A Risky Investment?
Apr 04Why Avantor, Inc. (NYSE:AVTR) Could Be Worth Watching
Mar 22Avantor Non-GAAP EPS of $0.32 beats by $0.02, revenue of $1.8B beats by $10M
Feb 03Does This Valuation Of Avantor, Inc. (NYSE:AVTR) Imply Investors Are Overpaying?
Feb 02Avantor: Re-Rating To Buy, Paying Fair Price At 17x Forward P/E (Rating Upgrade)
Jan 28With EPS Growth And More, Avantor (NYSE:AVTR) Makes An Interesting Case
Jan 09Here's Why Avantor (NYSE:AVTR) Can Manage Its Debt Responsibly
Dec 27Is It Time To Consider Buying Avantor, Inc. (NYSE:AVTR)?
Dec 14Avantor: Reduce To Hold, Awaiting Convergence Of Price, Fundamentals
Nov 10Avantor Non-GAAP EPS of $0.34 beats by $0.01, revenue of $1.86B beats by $10M
Oct 28Estimating The Intrinsic Value Of Avantor, Inc. (NYSE:AVTR)
Oct 27Avantor raised to Buy at Citi on valuation disconnect
Oct 05Do Avantor's (NYSE:AVTR) Earnings Warrant Your Attention?
Oct 03We Think Avantor (NYSE:AVTR) Can Stay On Top Of Its Debt
Sep 21Is Avantor, Inc. (NYSE:AVTR) Potentially Undervalued?
Sep 09Avantor Non-GAAP EPS of $0.37 misses by $0.01, revenue of $1.91B misses by $70M
Jul 28Estimating The Intrinsic Value Of Avantor, Inc. (NYSE:AVTR)
Jul 18수익 및 비용 분석
수익 및 비용 분석
Avantor 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.
수익 및 매출 내역
| 날짜 | 수익 | 수익 | G+A 비용 | R&D 비용 |
|---|---|---|---|---|
| 30 Sep 24 | 6,820 | 310 | 1,616 | 0 |
| 30 Jun 24 | 6,826 | 360 | 1,545 | 0 |
| 31 Mar 24 | 6,867 | 260 | 1,497 | 0 |
| 31 Dec 23 | 6,967 | 321 | 1,466 | 0 |
| 30 Sep 23 | 7,039 | 364 | 1,470 | 0 |
| 30 Jun 23 | 7,176 | 423 | 1,475 | 0 |
| 31 Mar 23 | 7,342 | 610 | 1,469 | 0 |
| 31 Dec 22 | 7,512 | 662 | 1,457 | 0 |
| 30 Sep 22 | 7,625 | 598 | 1,442 | 0 |
| 30 Jun 22 | 7,603 | 572 | 1,445 | 0 |
| 31 Mar 22 | 7,551 | 534 | 1,463 | 0 |
| 31 Dec 21 | 7,386 | 508 | 1,426 | 0 |
| 30 Sep 21 | 7,269 | 466 | 1,442 | 0 |
| 30 Jun 21 | 7,040 | 267 | 1,388 | 0 |
| 31 Mar 21 | 6,660 | 169 | 1,345 | 0 |
| 31 Dec 20 | 6,394 | 52 | 1,342 | 0 |
| 30 Sep 20 | 6,127 | 71 | 1,336 | 0 |
| 30 Jun 20 | 6,026 | 135 | 1,332 | 0 |
| 31 Mar 20 | 6,079 | -226 | 1,334 | 0 |
| 31 Dec 19 | 6,040 | -335 | 1,329 | 0 |
| 30 Sep 19 | 5,990 | -514 | 1,294 | 0 |
| 30 Jun 19 | 5,981 | -554 | 1,303 | 0 |
| 31 Mar 19 | 5,926 | -330 | 1,305 | 0 |
| 31 Dec 18 | 5,864 | -356 | 1,321 | 0 |
| 30 Sep 18 | 5,120 | -639 | 1,215 | 0 |
| 31 Dec 17 | 1,247 | -415 | 376 | 0 |
| 31 Dec 16 | 691 | -42 | 257 | 0 |
| 31 Dec 15 | 637 | 22 | 185 | 0 |
양질의 수익: AVTR 은 높은 수익을 보유하고 있습니다.
이익 마진 증가: AVTR 의 현재 순이익 이익률 (4.5%) 작년보다 낮습니다 (5.2%).
잉여현금흐름 대 수익 분석
과거 수익 성장 분석
수익추이: AVTR 지난 5년 동안 수익을 창출하여 매년 37.4% 수익을 올렸습니다.
성장 가속화: AVTR 은(는) 지난 1년 동안 마이너스 수익 성장을 기록했기 때문에 5년 평균과 비교할 수 없습니다.
수익 대 산업: AVTR 은 지난 1년 동안 마이너스 수익 성장( -15% )을 기록하여 Life Sciences 업계 평균( -4.7% ).
자기자본 수익률
높은 ROE: AVTR 의 자본 수익률( 5.6% )은 낮음으로 간주됩니다.